Published in Dig Dis Sci on July 01, 2002
Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut (2010) 1.47
Association of Helicobacter species with hepatitis C cirrhosis with or without hepatocellular carcinoma. Gut (2005) 1.34
Cross-reactivity between immune responses to Helicobacter bilis and Helicobacter pylori in a population in Thailand at high risk of developing cholangiocarcinoma. Clin Vaccine Immunol (2008) 0.88
Adherence, internalization, and persistence of Helicobacter pylori in hepatocytes. Dig Dis Sci (2008) 0.83
Distance burning: how gut microbes promote extraintestinal cancers. Gut Microbes (2011) 0.83
Helicobacter pylori may play a contributory role in the pathogenesis of primary sclerosing cholangitis. Dig Dis Sci (2007) 0.82
Helicobacter pylori infection does not promote hepatocellular cancer in a transgenic mouse model of hepatitis C virus pathogenesis. Gut Microbes (2013) 0.81
Disturbance of apoptosis and DNA synthesis by Helicobacter pylori infection of hepatocytes. Dig Dis Sci (2008) 0.81
Association between the presence of H pylori in the liver and hepatocellular carcinoma: a meta-analysis. World J Gastroenterol (2008) 0.81
Detection of Helicobacter pylori in paraffin-embedded specimens from patients with chronic liver diseases, using the amplification method. Dig Dis Sci (2008) 0.81
Extragastric manifestations of Helicobacter pylori infection: Possible role of bacterium in liver and pancreas diseases. World J Hepatol (2015) 0.78
Low frequency of Helicobacter DNA in benign and malignant liver tissues from Baltimore, United States. Hum Pathol (2007) 0.77
The effect of Helicobacter pylori eradication on liver enzymes in patients referring with unexplained hypertransaminasemia. Adv Biomed Res (2014) 0.76
Helicobacter Pylori DNA in Liver Tissues From Chronic Hepatitis C Egyptian Patients. Gastroenterology Res (2011) 0.75
Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology (1994) 7.89
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol (1995) 4.68
Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel Helicobacter species. J Natl Cancer Inst (1994) 4.59
Hepatic Helicobacter species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis. Gastroenterology (1998) 4.30
Helicobacter bilis sp. nov., a novel Helicobacter species isolated from bile, livers, and intestines of aged, inbred mice. J Clin Microbiol (1995) 3.74
A sensitive and specific serologic test for detection of Campylobacter pylori infection. Gastroenterology (1989) 3.66
Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg (1990) 3.25
Helicobacter pullorum sp. nov.-genotype and phenotype of a new species isolated from poultry and from human patients with gastroenteritis. Microbiology (1994) 2.79
Chronic active hepatitis in mice caused by Helicobacter hepaticus. Am J Pathol (1994) 2.45
Relationship of vacA genotypes of Helicobacter pylori to cagA status, cytotoxin production, and clinical outcome. Helicobacter (1998) 2.39
Helicobacter species identified in liver from patients with cholangiocarcinoma and hepatocellular carcinoma. Gastroenterology (2001) 2.04
Detection of microcystins, a blue-green algal hepatotoxin, in drinking water sampled in Haimen and Fusui, endemic areas of primary liver cancer in China, by highly sensitive immunoassay. Carcinogenesis (1996) 1.65
Mechanisms involved in Helicobacter pylori-induced inflammation. Gastroenterology (1993) 1.49
Helicobacter canadensis sp. nov. isolated from humans with diarrhea as an example of an emerging pathogen. J Clin Microbiol (2000) 1.47
Detection of Helicobacter species in the liver of patients with and without primary liver carcinoma. Cancer (2000) 1.44
Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol (1996) 1.40
Helicobacter canis isolated from a dog liver with multifocal necrotizing hepatitis. J Clin Microbiol (1996) 1.27
Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology (1993) 1.23
Helicobacter infection and cirrhosis in hepatitis C virus carriage: is it an innocent bystander or a troublemaker? Med Hypotheses (2000) 1.20
Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol (1994) 1.17
Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of Helicobacter pylori infection. Aliment Pharmacol Ther (1998) 1.06
High prevalence of Helicobacter pylori in liver cirrhosis: relationship with clinical and endoscopic features and the risk of peptic ulcer. Dig Dis Sci (1997) 1.03
Extradigestive manifestations of Helicobacter pylori infection: fact and fiction. Dig Dis Sci (1999) 0.97
Marked differences in the frequency of microsatellite instability in gastric cancer from different countries. Am J Gastroenterol (1999) 0.95
Persistent infection by Helicobacter pylori down-modulates virus-specific CD8+ cytotoxic T cell response and prolongs viral infection. J Infect Dis (1998) 0.92
Seroprevalence of Helicobacter pylori infection in patients with hepatitis B. Br J Biomed Sci (1998) 0.87
Silent cirrhosis in patients with hepatocellular carcinoma. Implications for screening in high-incidence and low-incidence areas. Cancer (1990) 0.85
Hepatitis C virus and hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol (1999) 0.76
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut (2012) 12.62
Traces of human migrations in Helicobacter pylori populations. Science (2003) 11.92
Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis (2002) 5.09
Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology (2008) 3.89
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
Norwalk virus shedding after experimental human infection. Emerg Infect Dis (2008) 3.70
Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol (2005) 3.34
Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology (2002) 3.27
The peopling of the Pacific from a bacterial perspective. Science (2009) 3.14
Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol (2012) 2.99
Gastroesophageal reflux among different racial groups in the United States. Gastroenterology (2004) 2.87
Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet (2002) 2.71
Helicobacter pylori in North and South America before Columbus. FEBS Lett (2002) 2.57
HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci (2006) 2.53
Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis (2013) 2.50
A report card to grade Helicobacter pylori therapy. Helicobacter (2007) 2.41
Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology (2002) 2.32
Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis (2010) 2.21
Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol (2009) 2.15
LIN28B promotes colon cancer progression and metastasis. Cancer Res (2011) 2.05
Comparing the Blatchford and pre-endoscopic Rockall score in predicting the need for endoscopic therapy in patients with upper GI hemorrhage. Gastrointest Endosc (2010) 2.04
Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology (2005) 2.03
An inter- and intra-laboratory comparison of breath ¹³CO₂analysis. Aliment Pharmacol Ther (2003) 2.03
Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter (2009) 2.02
Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol (2011) 1.98
Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. J Exp Med (2005) 1.90
Gastritis staging in clinical practice: the OLGA staging system. Gut (2006) 1.90
Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci U S A (2012) 1.82
Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110δ. Gastroenterology (2010) 1.80
Risk factors for immediate and delayed bleeding associated with endoscopic submucosal dissection of gastric neoplastic lesions. Scand J Gastroenterol (2009) 1.75
NSAIDs, Helicobacter pylori, and Pandora's Box. N Engl J Med (2002) 1.75
Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol (2002) 1.74
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter (2011) 1.73
Discrimination between cases of duodenal ulcer and gastritis on the basis of putative virulence factors of Helicobacter pylori. J Clin Microbiol (2002) 1.72
Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer (2002) 1.69
Biliary stenting in the management of large or multiple common bile duct stones. Gastrointest Endosc (2010) 1.68
Why do African Americans get more colon cancer than Native Africans? J Nutr (2007) 1.64
Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol (2009) 1.62
Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infection. Gastroenterology (2004) 1.59
Helicobacter pylori infection in mice: Role of outer membrane proteins in colonization and inflammation. Gastroenterology (2002) 1.58
Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol (2005) 1.57
Endoscopic demonstration of transient small bowel intussusception in a patient with adult celiac disease. Gastrointest Endosc (2003) 1.55
Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol (2012) 1.51
Horizontal versus familial transmission of Helicobacter pylori. PLoS Pathog (2008) 1.48
Helicobacter pylori eradication and change in markers of iron stores among non-iron-deficient children in El Paso, Texas: an etiologic intervention study. J Pediatr Gastroenterol Nutr (2011) 1.47
Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol (2009) 1.45
Helicobacter pylori virulence factors: facts and fantasies. Curr Opin Gastroenterol (2005) 1.44
[Logical structure of the problem oriented clinical record. A combined Popper-Bayes approach]. Ann Ital Med Int (2002) 1.44
Etest for metronidazole susceptibility in H. pylori: use of the wrong standard may have led to the wrong conclusion. Am J Gastroenterol (2004) 1.43
Effect of the carbonic anhydrase inhibitor, acetazolamide, on Helicobacter pylori infection in vivo: a pilot study. Helicobacter (2005) 1.42
Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol (2012) 1.41
Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J Immunol (2006) 1.41
Double-blind randomized trial of quadruple sequential Helicobacter pylori eradication therapy in asymptomatic infected children in El Paso, Texas. J Pediatr Gastroenterol Nutr (2011) 1.40
MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int J Clin Exp Pathol (2009) 1.38
Helicobacter pylori infection--a boon or a bane: lessons from studies in a low-prevalence population. Helicobacter (2013) 1.38
Regulation of interleukin-6 promoter activation in gastric epithelial cells infected with Helicobacter pylori. Mol Biol Cell (2005) 1.37
Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med (2002) 1.35
Molecular epidemiology and outcome of Helicobacter pylori infection in Thailand: a cultural cross roads. Helicobacter (2004) 1.35
Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island. Am J Gastroenterol (2002) 1.34
An anti-inflammatory role for carbon monoxide and heme oxygenase-1 in chronic Th2-mediated murine colitis. J Immunol (2011) 1.31
Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol (2011) 1.30
Helicobacter pylori infection in Kazakhstan: effect of water source and household hygiene. Am J Trop Med Hyg (2002) 1.29
Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol (2013) 1.28
Correlation between Helicobacter pylori OipA protein expression and oipA gene switch status. J Clin Microbiol (2004) 1.27
Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am (2010) 1.26
Helicobacter pylori and hetertopic gastric mucosa in the upper esophagus (the inlet patch). Am J Gastroenterol (2003) 1.25
HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis (2006) 1.24
Amelioration of chronic murine colitis by peptide-mediated transduction of the IkappaB kinase inhibitor NEMO binding domain peptide. J Immunol (2007) 1.22
Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. Scand J Gastroenterol (2007) 1.22
Helicobacter pylori virulence and cancer pathogenesis. Future Oncol (2014) 1.21
Cutting edge: transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer. J Immunol (2007) 1.21
Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter (2011) 1.21
An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep (2013) 1.21
Serological responses to experimental Norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay. Clin Vaccine Immunol (2011) 1.20
Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study. J Gastroenterol Hepatol (2012) 1.20
Helicobacter pylori activate epidermal growth factor receptor- and phosphatidylinositol 3-OH kinase-dependent Akt and glycogen synthase kinase 3beta phosphorylation. Cell Microbiol (2008) 1.19
Effect of antisecretory therapy on atypical symptoms in gastroesophageal reflux disease. Dig Dis Sci (2007) 1.19
Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. Gastroenterology (2002) 1.19
vacA i-region subtyping. Gastroenterology (2008) 1.18
Diet, lifestyle and gender in gastro-esophageal reflux disease. Dig Dis Sci (2007) 1.16
Management of gastric polyps: an endoscopy-based approach. Clin Gastroenterol Hepatol (2013) 1.15
Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis (2011) 1.14
Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut (2013) 1.14
Role of deletion located between the intermediate and middle regions of the Helicobacter pylori vacA gene in cases of gastroduodenal diseases. J Clin Microbiol (2009) 1.13
Comparison of genotyping Helicobacter pylori directly from biopsy specimens and genotyping from bacterial cultures. J Clin Microbiol (2003) 1.13
Regulation of RANTES promoter activation in gastric epithelial cells infected with Helicobacter pylori. Infect Immun (2005) 1.12
Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation (2002) 1.11
Molecular markers in Helicobacter pylori-associated gastric carcinogenesis. Clin Lab Med (2005) 1.11
The Role of CD44 in the Pathogenesis, Diagnosis, and Therapy of Gastric Cancer. Gut Liver (2011) 1.11
Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin Vaccine Immunol (2011) 1.10
Which Therapy for Helicobacter pylori Infection? Gastroenterology (2012) 1.10
Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol (2013) 1.09
Genetic analysis of Helicobacter pylori strain populations colonizing the stomach at different times postinfection. J Bacteriol (2007) 1.09
Gastric mucosal interleukin-17 and -18 mRNA expression in Helicobacter pylori-induced Mongolian gerbils. Cancer Sci (2009) 1.09
Strategy for eliminating gastric cancer in Japan. Helicobacter (2010) 1.08